S&P 500

7,483.24

0.00%

Dow Jones

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

ホーム
投資
株式
アメリカ
NYSE
Prime Impact Acquisition I (PIAI)
Prime Impact Acquisition I (PIAI) ニュース

Prime Impact Acquisition I (PIAI)

10.82

0.00

(0.00%)

終了 7月4日 5:00AM

0.00

(0.00%)

取引時間後: -

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Cheche Group Inc. and Prime Impact Complete Business Combination

Cheche Group Inc. and Prime Impact Complete Business Combination PR Newswire BEIJING and SAN JOSE, Calif., Sept. 18, 2023 Cheche's Class A...

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Current Report Filing (8-k)

false 0001819175 0001819175 2023-06-14 2023-06-14 0001819175 piai:UnitsEachConsistingOfOneClassAOrdinaryShareAndOneThirdOfOneWarrantToAcquireOneC...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Filed by Cheche Group Inc. and Cheche Technology Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed...

Current Report Filing (8-k)

false 0001819175 0001819175 2023-06-05 2023-06-05 0001819175 piai:UnitsEachConsistingOfOneClassAOrdinaryShareAndOneThirdOfOneWarrantToAcquireOneC...

rosemountbomber 4分前

I agree with your thinking and also what needs to be considered is after decimating the board, just a desire to be acquired doesn’t automatically make that happen. Some other party has to be interested in acquiring Amarin. What happens then if no one steps up?

AMRN

chereb19 5分前

This is another post built on false equivalence. Sharing Y-90 doesn't make two products the same any more than sharing aspirin makes every painkiller identical.

You keep calling them competitors while ignoring they're fundamentally different technologies. One is a hydrogel platform, t

RDGL

NASDAQ2020 6分前

Im glad I held my shares past $0.15

ELTP

Idunno 6分前

And don’t forget your buddy, AF. … .. .

NWBO

Doc logic 6分前

HappyLibrarian,

You are mistakenly overstating my claim which is a common problem so no harm no foul. Manufacturing transition preparedness is what I am suggesting must be in place. Artisan will be utilized to start as NWBO has consistently stated and the MIA is based on that model.

NWBO

rcaselli 7分前

Just knowing JCTB1 is here is good enuf for me, okay.
See ya all topside….
$LBRG

LBRG

Idunno 7分前

Have at it Brazen! ;) … .. . :)

NWBO

CatfishHunter 9分前

Every biotech founder believes their design choice was the right one — that’s true of BetaGlue’s surgeon-founder and it was true of Fisher/Korenko too. Design rationale explains intent, not outcome. The question that matters is what the trial data shows for each product, not why either team picked t

RDGL

asp42001 9分前

Digital USIO & AI Payment Potential:

(USIO In-Part):

"Embedded payments are the hidden engine under the hood of the apps and platforms we use every day. When you buy a ticket through a sports app or pay for a round of golf lessons online, embedded payments are doing the

USIO

BigBadWolf 10分前

$Ownership😘 of @ this point w/ irrefutable DD
🤔https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177573771&txt2find=reactor

AMFN

mgland 11分前

https://x.com/thommic/status/2072760144774005081

GTF 11分前

Just so you know the clock on the 12 month restricted period for SNTX divvy shares began on June 17th, 2026. It doesn't matter that the deliverance of shares to the gtvh shareholders is taking some time. The clock begins when SNTX creates and issues the shares...meaning the day OTCmarkets shows the

GTVH

manibiotech 13分前

I like this line in couple of PSM analysis slides:

“ Conclusion: Based on these more precisely matched comparisons,
the survival benefit with DCVax-L was likely underestimated
in the original analysis”

Very encouraging . Now let’s see when MHRA does its jo

NWBO

ErnieBilco 14分前

Good to know because I was thinking about letting it go but now I have a reason to hold

AMLX

gdog 14分前

This is by far the Best piece Gary has written imho

https://garywallach.substack.com/p/from-qualification-to-harvest-could?r=3iu9hl&utm_campaign=post&utm_medium=web&triedRedirect=true

NLST

AngeloFoca 15分前

I doubt you will agree or bother reading what I have said but at least it wasn’t written by some AI.
I have read it all and you are right... I don't agree with ANY of it.

No, I don't believe they have done EVERYTHING right... But I do believe that had it been any other CEO...

NWBO

rmoss 16分前

Stay away stay very far away........

HCMC

flipper44 17分前

I’m busy today, but these results are in line with what I expected. Excellent, and very helpful for all current and potential stakeholders. Great for patients! For current therapy as well as future improvements with combination therapy. Happy 4th Tomorrow! (Top notch for valuation)

NWBO

stoxjock 17分前

Ok, This Explains it. I didn't know which Wall St (Or elsewhere in Europe like James St) Scoundrel "Creditors' were "Filing TWICE or even More' to get their Money from multiple Lehman Entities ..Frankly, those SCUM should be prosecuted for Fraud and Thrown in Jail for Good...

LEHNQ

SC8 18分前

They didn't go to Europe. They're already there. It's an Italian company! Y90 has no shelf life. To do a trial outside of manufacturing continent is a complete waste of time, as RDGL has well demonstrated already. One company has competent leadership and one doesn't. One company is over 4 year

RDGL

nowwhat2 18分前

What're you waiting for ?......

Drink

https://investorshub.advfn.com/uimage/uploads/2026/7/3/eg[hqgutsi_group_for_health_logo.jpg

.

VMHG

HillsideManor 19分前

I believe it was published by a standard member, right after the microcap club conference in June. I'm hoping that will help get a lot more eyes on it.

LCTC

Doc logic 19分前

flipper44,

Thanks for explaining this. Just to be clear for others, you are describing OS as an absolute number (can’t change) from the data in the trial. The comparator number is what can change based on the methods utilized to measure SOC/placebo benefit. This difference in measu

NWBO

RafterAbarJ 19分前

The interesting thing was the companies that thought Elite was too big for them to purchase. Makes me think that the acceptable sale price is significantly higher than where we are now. I’d like to know the number they have in mind.

ELTP

HenryB3 19分前

The Scam is getting called out by alot of the bagholders now, eh? PUMP and DUMP city is where your at. The Path is south. Typical OTC lies and rumors. SUB 12 and that's being very nice!

ELTP

NYSE

PIAI

Prime Impact Acquisition I

iShares Developed Market...

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Prime Impact Acquisition I (PIAI)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ